



**2nd Annual MI4 Scientific Symposium:
New Frontiers in Immuno-Oncology**

**Friday, December 4th, 2020
08h45-15h30**

08h45-09h00 WELCOME

Dr. Marie Hudson, Co-Director (Immunity), McGill Interdisciplinary Initiative in Infection and Immunity

Suzanne Fortier, Principal and Vice-Chancellor, McGill University

David H. Eidelman, Vice-Principal (Health Affairs), Dean of the Faculty of Medicine and Health Sciences, McGill University

09h00-09h20 MI4 State of the Union

Dr. Donald Sheppard, Director, McGill Interdisciplinary Initiative in Infection and Immunity

09h20-10h15 MI4 Highlights

Dr. Todd Lee, Dr. Nicole Basta, Dr. Jonathan Campbell, Dr. Mathieu Maheu-Giroux, Dr. Cecile Rousseau

(Each of the five presentations will be 6-7 minutes long)

9h50-10h15 Panel discussion for Q&A (Moderator: Dr. Sheppard)

10h15-10h30 MI4 Year in Preview

Dr. Marcel Behr, Co-Director (Infection), McGill Interdisciplinary Initiative in Infection and Immunity

10h30-11h00 BREAK

11h00-11h45 KEYNOTE I

Keynote Introduction: Dr. Jonathan Spicer, Director, McGill Thoracic Oncology Network

Neoadjuvant Immune Checkpoint Blockade

Drew Mark Pardoll, M.D., Ph.D., Abeloff Professor of Oncology; Director, Bloomberg~Kimmel Institute for Cancer Immunotherapy; Director, Cancer Immunology Program, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine

11h35-11h45 Question period

11h45-12h15 LUNCH

12h15-13h15 BREAKOUT SESSION I (Choice of one of the following two)

1. TRAINEE PRESENTATIONS (Moderator: Dr. Christopher Rudd)

(Each of the five presentations will be 5 minutes long. Trainee presentations will be chosen from the winners of a poster competition)

12h50-13h15 Panel discussion for Q&A

Or...

2. FOCUSED NETWORKING

13h15-14h15 BREAKOUT SESSION II (Choice of one of the following pairs)

**1. The role of the microbiome in cancer immunotherapy
(Moderator: Dr. Irah King)**

13h15-13h35 Bertrand Routy, M.D., PhD, Director, Laboratory of Immunotherapy, Assistant Professor of Hematology-oncology, Université de Montréal

Gut microbiome the new target to overcome cancer immunotherapy resistance

13h35-13h55 Kathy McCoy, Professor of Physiology & Pharmacology; Director, IMC Germ-free Program, Cumming School of Medicine, University of Calgary

How early life host-microbial interactions shape immune responses to cancer in adult life

13h55-14h15 (20 minutes at the end of both presentations for Q&A)

Or...

**2. Immune-related adverse events from cancer immunotherapies
(Moderator: Dr. Marie Hudson)**

13h15-13h35 Khashayar Esfahani, M.D., M.Sc., FRCPC, Assistant Professor, Department of Oncology, McGill University

Power unleashed: tales of immune-related adverse reactions

13h35-13h55 Logan Walsh, PhD, Rosalind Goodman Lung Cancer Chair
Rosalind and Morris Goodman Cancer Research Centre, Department of Human Genetics,
McGill University

Developing novel animal models to study the immune complications of immunotherapy

13h55-14h15 (20 minutes at the end of both presentations for Q&A)

Or...

3. MI4 funded research in immuno-oncology
(Moderator: Dr. Ciriaco Piccirillo)

13h15-13h35 Ian Watson, Canada Research Chair II in Functional Genomics of
Melanoma; Member of the Goodman Cancer Research Centre; Assistant Professor,
Department of Biochemistry, McGill University

The Immune Landscape of Melanoma

13h35-13h55 Sonia Del Rincon, Assistant Professor, Gerald Bronfman Department of
Oncology, McGill University; Investigator, Lady Davis Institute, Segal Cancer Centre-
Jewish General Hospital

The MNK1/2-eIF4E axis as a driver of oncogenic progression and therapeutic target

13h55-14h15 (20 minutes at the end of both presentations for Q&A)

14h15-14h30 BREAK

14h30-15h15 KEYNOTE II

Keynote Introduction: Dr. Gerald Batist, Director, Segal Cancer Centre; Scientific
Director, Montreal Centre for Experimental Therapeutics in Cancer; Director, McGill
University Centre for Translational Research in Cancer; Chair, Department of Oncology,
McGill University; Professor, Departments of Medicine and Oncology, McGill University

**Microbial Based Immunotherapy: Can we make friends with an enemy
to kill cancer?**

Daniel Saltzman, MD, PhD, Professor of Surgery and Pediatrics, AS Leonard
Endowed Chair in Pediatric Surgery; Chief of Pediatric Surgery, University of Minnesota
Medical School

15h05-15h15 Question period

15h15-15h30 CLOSING REMARKS

Dr. Marie Hudson Co-Director (Immunity), McGill Interdisciplinary Initiative in
Infection and Immunity